BCTX - BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
(NewsDirect)
The world of biotechis having whatsome are calling a golden age . Many companies are presentingnew and innovative drugs to the FDA for approval and later the publicfor consumption. SmartBeta EFTs like SPDR S&P Biotech (NYSEARCA: XBI)(“XBI”) and iShares Biotechnology (NASDAQ: IBB) (“IBB”) arebringing a lot of awareness and attention to the field for investorsto get excited about.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”) presented positive initialefficacy data in its 2021-2022 cohort of 12 advanced breast cancerpatients for its clinical study of Bria-IMT™ immunotherapy treatmentduring the Society for Immunotherapy of Cancer (SITC) 37th AnnualMeeting.
Breastcancer is still one of the deadliest cancers globally. Eachyear in the U.S. there are about 264,000 new diagnoses and about42,000 women and 500 men die each year from breast cancer. The averagerisk that a woman will develop breast cancer sometime in her lifetimeis around 13%. For certain populations that risk is higher; breastcancer is the number one cause of cancer death for Hispanicwomen.
BriaCell isan immuno-oncology-focused biotechnology company developing targetedand effective approaches for the management of cancer. BriaCell’slead candidate Bria-IMT is marketed as an off-the-shelf personalizedcellular approach to immunotherapy for the treatment of advanced solidtumors. The targeted patients are advanced breast cancer patients orterminal breast cancer patients.
TheBria-IMT™ study showed disease control, tumor shrinkage, andpotential survival benefits among 12 patients in Phase I/IIa when incombination with Incyte’s retifanlimab. 70% of patients showedeither disease control or progression-free survival benefits comparedwith their previous therapy attempts.
Prior to the BriaCell study, the 12 patients hadeach failed at least 2 previous attempts at therapy regimens likechemotherapy or “targeted” therapy. The Bria-IMT clinical successis arguably even more impressive with this in mind.
“We are very pleased to report that ourcombination therapy with Incyte’s retifanlimab produced clearevidence of tumor shrinkage and showed potential survival benefit inheavily pre-treated advanced breast cancer patients,” statedDr. William V. Williams, BriaCell’s President & CEO. “We interpret these results to offer a potential opportunityfor treatment in otherwise terminal patients. It’s very important toemphasize that these responses and clinical benefit occurred in womenwith advanced-stage breast cancer who have exhausted other treatmentoptions.”
What Else Does BriaCell Have In ThePipeline?
BriaCell also reports it is currently developingnext-generation off-the-shelf personalized immunotherapies targetingpatients with advanced breast cancer and advanced prostate cancer.Bria-OTS+™, for advanced breast cancer, and Bria-PROS™, foradvanced prostate cancer, are designed to activate naïve T cells andproduce a strong immune response in patients.
The company is impressed with the currentdata showing the ability of Bria-OTS+™ and Bria-PROS™ to boost theimmune system response and produce strong anti-tumor responses inpatients with advanced cancers.
BriaCell is animmuno-oncology-focused biotechnology company developing targeted andeffective approaches for the management of cancer.
Thispost contains sponsored advertising content. This content is forinformational purposes only and is not intended to be investingadvice.
Contact Details
CORE IR
CompanyWebsite
Copyright (c) 2022 TheNewswire - All rights reserved.